Bristol Myers Squibb (BMS) presented 18 analyses at the 66th American Society of Hematology (ASH) Annual Meeting, showcasing the...

A five-year follow-up analysis of the ZUMA-5 Phase 2 study shows promising results for Yescarta (axicabtagene ciloleucel) in patients...

Kite, a Gilead Company, presented promising data on Tecartus (brexucabtagene autoleucel) for relapsed/refractory mantle cell lymphoma (R/R MCL) and...

The DREAMM-7 trial interim analysis revealed that belantamab mafodotin combined with bortezomib and dexamethasone (BVd) significantly improved overall survival...

Star Therapeutics announced interim Phase 1 clinical trial data for VGA039, a novel subcutaneous monoclonal antibody for Von Willebrand...

On December 1, 2024, the European non-profit organization noyb (None of Your Business), co-founded by privacy advocate Max Schrems,...

In a conversation with Dr. Stephanie Manson Brown, Head of Clinical Development at Allergan Aesthetics, we explore the company’s initiatives to...

At the SCOPE EU conference, Julius Kusserow, an R&D Standards Expert at Bayer AG, presented a transformative vision for...

Stoke Therapeutics announced positive data from Phase 1/2a and open-label extension (OLE) studies of zorevunersen, a drug candidate for...

PureTech Health presented positive Phase 1b trial data for LYT-200, a novel anti-galectin-9 monoclonal antibody, in patients with relapsed...